Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 375-379

  Li, Fang ^a   Nandy, Partha ^b   Chien, Shuchean ^b   Noel, Gary J ^b   Tornoe, Christoffer W ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADOLESCENT; ADULT; ANTHRAX; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; INFANT; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPTIMAL DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SIMULATION; SINGLE DRUG DOSE; STEADY STATE; TREATMENT OUTCOME;

ADOLESCENT; AGING; ANTHRAX; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; INHALATION EXPOSURE; INJECTIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; MALE; OFLOXACIN; SPORES, BACTERIAL; TABLETS;

EID: 73849139599     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00667-09     Document Type: Article

References (11)

1. Bhattaram, V. A., C. Bonapace, D. M. Chilukuri, J. Z. Duan, C. Garnett, J. V. Gobburu, S. H. Jang, L. Kenna, L. J. Lesko, R. Madabushi, Y. Men, J. R. Powell, W. Qiu, R. P. Ramchandani, C. W. Tornoe, Y. Wang, and J. J. Zheng. 2007. Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81:213-221.
2. Bhattaram, V. A., B. P. Booth, R. P. Ramchandani, B. N. Beasley, Y. Wang, V. Tandon, J. Z. Duan, R. K. Baweja, P. J. Marroum, R. S. Uppoor, N. A. Rahman, C. G. Sahajwalla, J. R. Powell, M. U. Mehta, and J. V. Gobburu. 2005. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 7:E503-E512.
3. Bradley, J. S., A. Arguedas, J. L. Blumer, X. Saez-Llorens, R. Melkote, and G. J. Noel. 2007. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr. Infect. Dis. J. 26:868-878.
4. Center for Drug Evaluation and Research, United States Food and Drug Administration. Accessed 12 December 2008. Guidance for industry. Exposure-response relationships - study design, data analysis, and regulatory applications. http://www.fda.gov/cder/guidance/5341.fnl.pdf.
5. Committee on Infections. 2009. Anthrax, p. 212-213. In Red book. Report of the Committee on Infectious Diseases, 30th ed. American Academy of Pediatrics, Elk Grove Village, IL.
6. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287: 2236-2252.
7. Kao, L. M., K. Bush, R. Barnewall, J. Estep, F. W. Thalacker, P. H. Olson, G. L. Drusano, N. Minton, S. Chien, A. Hemeryck, and M. F. Kelley. 2006. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob. Agents Chemother. 50:3535-3542.
8. Noel, G. J., J. S. Bradley, R. E. Kauffman, C. M. Duffy, P. G. Gerbino, A. Arguedas, P. Bagchi, D. A. Balis, and J. L. Blumer. 2007. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr. Infect. Dis. J. 26:879-891.
9. Milsap, R. L., M. R. Hill, and S. J. Szefler. 1992. Pharmacokinetic considerations in children. In W. E. Evans, J. J. Schentag, and W. J. Jusk (ed.), Applied pharmacokinetics principles of therapeutic drug monitoring, 3rd ed. Lippincott Williams & Wilkins, Philadelphia, PA.
10. Schadd, U. B. 2000. Use of quinolones in pediatrics, p. 455-476. In V. T. Andriole (ed.), The quinolones, 3rd ed. Academic Press, New York, NY.
11. Tornøe, C. W., J. J. Tworzyanski, M. A. Imoisili, J. J. Alexander, J. M. Korth-Bradley, and J. V. Gobburu. 2007. Optimising piperacillin/tazobactam dosing in paediatrics. Int. J. Antimicrob. Agents 30:320-324.